Related Experiment Video
Updated: May 14, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Topical ranibizumab as a treatment of corneal neovascularization
Giulio Ferrari1, Mohammad H Dastjerdi, Andre Okanobo
1G.B. Bietti Eye Foundation-IRCCS, Rome, Italy. giulio.ferrari@schepens.harvard.edu
Purpose:
To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).
Methods:
This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.
Results:
Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.
Conclusions:
Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Diabetic Retinopathy
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...